{"id":"tixagevimab-cilgavimab","safety":{"commonSideEffects":[{"rate":"null","effect":"Injection site pain"},{"rate":"null","effect":"Fatigue"},{"rate":"null","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL4650258","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Tixagevimab and cilgavimab are designed to provide long-lasting protection against SARS-CoV-2 infection by targeting the spike protein, which is essential for the virus to enter host cells. By binding to the spike protein, these antibodies prevent the virus from attaching to and entering host cells, thereby reducing the risk of infection.","oneSentence":"Tixagevimab and cilgavimab are monoclonal antibodies that bind to the SARS-CoV-2 spike protein, preventing viral entry into host cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:38:59.242Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of COVID-19 in individuals 12 years of age and older"}]},"trialDetails":[{"nctId":"NCT07473986","phase":"","title":"REAl LIfe\" Observational Study on the Effectiveness of Evusheld Prophylaxis Against SARS-CoV-2 Omicron Variants in Vaccine Non-responder Immunocompromised Patients","status":"COMPLETED","sponsor":"Fondazione IRCCS Policlinico San Matteo di Pavia","startDate":"2022-07-08","conditions":"SARS-CoV-2 Omicron Variants","enrollment":88},{"nctId":"NCT05041907","phase":"PHASE2","title":"Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)","status":"RECRUITING","sponsor":"University of Oxford","startDate":"2021-09-30","conditions":"COVID-19","enrollment":3800},{"nctId":"NCT05281601","phase":"PHASE1","title":"AZD7442 Pharmacokinetics, Pharmacodynamics, and Safety Evaluation in Pediatrics","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-03-21","conditions":"SARS-CoV-2","enrollment":46},{"nctId":"NCT05648110","phase":"PHASE2, PHASE3","title":"Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA) Sub-study: Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA) Sub-study","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-12-16","conditions":"COVID-19, SARS-CoV-2","enrollment":3882},{"nctId":"NCT05780437","phase":"PHASE3","title":"AZD7442 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-02-10","conditions":"COVID-19","enrollment":1455},{"nctId":"NCT05712096","phase":"","title":"eVusheld Assessment reaL wORld Effectiveness in Israel Clalit Health Services","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2023-03-09","conditions":"SARS-CoV-2, COVID-19","enrollment":4000},{"nctId":"NCT04625725","phase":"PHASE3","title":"Phase III Double-blind, Placebo-controlled Study of AZD7442 for Pre-exposure Prophylaxis of COVID-19 in Adult.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2020-11-21","conditions":"COVID-19","enrollment":5197},{"nctId":"NCT05166421","phase":"PHASE1","title":"Study to Evaluate Pharmacokinetic Comparability Between AZD7442 Co-formulation (AZD8895 + AZD1061) vs AZD8895 and AZD1061 Individually in Adult Healthy Participants","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2021-11-30","conditions":"Corona Virus Disease","enrollment":224},{"nctId":"NCT05184062","phase":"PHASE2","title":"A Study to Evaluate the Safety and Tolerability of AZD7442 in Chinese Adults","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2021-12-03","conditions":"Coronavirus Disease 2019 (COVID-19)","enrollment":272},{"nctId":"NCT05667116","phase":"","title":"eVusheld Assessment reaL wORld Effectiveness at UPMC","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2023-01-09","conditions":"SARS-CoV-2, COVID-19","enrollment":4232},{"nctId":"NCT05271929","phase":"PHASE3","title":"Early High-Titre Convalescent Plasma in Clinically Vulnerable Individuals With Mild COVID-19","status":"TERMINATED","sponsor":"Deutsches Rotes Kreuz DRK-Blutspendedienst Baden-Wurttemberg-Hessen","startDate":"2022-04-01","conditions":"COVID-19","enrollment":120},{"nctId":"NCT05375760","phase":"PHASE2","title":"A Randomized, Open-label, Dose-ranging Study in Adults and Pediatric Individuals ≥ 12 Years of Age to Assess the Safety, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of AZD7442, for Pre-exposure Prophylaxis of COVID-19","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2022-06-09","conditions":"Coronavirus Disease 2019 (COVID-19)","enrollment":251},{"nctId":"NCT04507256","phase":"PHASE1","title":"AZD7442 - a Potential Combination Therapy for the Prevention and Treatment of COVID-19","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2020-08-18","conditions":"COVID-19","enrollment":60},{"nctId":"NCT04315948","phase":"PHASE3","title":"Trial of Treatments for COVID-19 in Hospitalized Adults","status":"COMPLETED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2020-03-22","conditions":"Corona Virus Infection","enrollment":1552},{"nctId":"NCT05569408","phase":"","title":"eVusheld Assessment reaL wORld Effectiveness in DoD Health System","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2023-08-10","conditions":"COVID-19; SARS-CoV-2; 2019 Novel Coronavirus Disease","enrollment":4724},{"nctId":"NCT05663957","phase":"","title":"eVusheld Assessment reaL wORld Effectiveness in the VA Health System","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2023-01-04","conditions":"SARS-CoV-2, COVID-19","enrollment":5814},{"nctId":"NCT04518410","phase":"PHASE2, PHASE3","title":"ACTIV-2: A Study for Outpatients With COVID-19","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-08-19","conditions":"Coronavirus, Covid19","enrollment":4044},{"nctId":"NCT05461378","phase":"","title":"PREP (Pre-Exposure Prophylaxis) of COVID-19","status":"COMPLETED","sponsor":"Ghady Haidar","startDate":"2022-07-26","conditions":"Immuno-Deficiency, COVID-19","enrollment":138},{"nctId":"NCT06156982","phase":"","title":"An Observational Study to Describe EVUSHELD™ (Tixagevimab/Cilgavimab) Pre-exposure Prophylaxis in Real-world Setting in Japan","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2023-12-06","conditions":"COVID-19","enrollment":397},{"nctId":"NCT05465876","phase":"PHASE2","title":"Passive Antibodies Against COVID-19 With EVUSHELD in Vaccine Non-responsive CLL","status":"WITHDRAWN","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2023-10","conditions":"Chronic Lymphocytic Leukemia, COVID-19","enrollment":""},{"nctId":"NCT05847140","phase":"","title":"A Non-interventional Multi-country Cohort Study to Assess the Safety of EVUSHELD™ During Pregnancy","status":"WITHDRAWN","sponsor":"AstraZeneca","startDate":"2022-06-27","conditions":"Pregnancy, Pregnant Women, Pregnancy Outcome","enrollment":""},{"nctId":"NCT05803395","phase":"","title":"Incidence of Severe COVID-19 Infection in Patients With CLL or B-NHL Who Received Pre-exposure Prophylaxis With Tixagevimab and Cilgavimab in Italy.","status":"UNKNOWN","sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","startDate":"2023-09-12","conditions":"Chronic Lymphocytic Leukemia, Indolent B-Cell Non-Hodgkin Lymphoma, COVID-19","enrollment":954},{"nctId":"NCT04625972","phase":"PHASE3","title":"Phase III Double-blind, Placebo-controlled Study of AZD7442 for Post- Exposure Prophylaxis of COVID-19 in Adults","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2020-12-02","conditions":"COVID-19","enrollment":1131},{"nctId":"NCT05321394","phase":"PHASE3","title":"Non-inferiority Trial on Treatments in Early COVID-19","status":"COMPLETED","sponsor":"Azienda Ospedaliera Universitaria Integrata Verona","startDate":"2022-03-07","conditions":"COVID-19","enrollment":536},{"nctId":"NCT05438498","phase":"PHASE3","title":"Real World Evaluation of the Effectiveness of AZD7442 for Prevention of SARS-CoV-2","status":"TERMINATED","sponsor":"MediMergent, LLC","startDate":"2022-06-03","conditions":"SARS-CoV-2 Infection","enrollment":550},{"nctId":"NCT04501978","phase":"PHASE3","title":"ACTIV-3: Therapeutics for Inpatients With COVID-19","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-08-04","conditions":"Covid19","enrollment":2753},{"nctId":"NCT05982704","phase":"PHASE4","title":"Study of Tixagevimab/Cilgavimab and Regdanvimab Efficacy for Treatment of COVID-19","status":"UNKNOWN","sponsor":"City Clinical Hospital No.52 of Moscow Healthcare Department","startDate":"2022-08-18","conditions":"Coronavirus Infections","enrollment":82},{"nctId":"NCT04723394","phase":"PHASE3","title":"Phase III Study of AZD7442 for Treatment of COVID-19 in Outpatient Adults","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2021-01-28","conditions":"COVID-19","enrollment":910},{"nctId":"NCT05437289","phase":"PHASE1","title":"A Study to Evaluate the Safety and Tolerability of AZD7442 in Healthy Chinese Adults","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2021-10-09","conditions":"Coronavirus Disease 2019 (COVID-19), Healthy Volunteer","enrollment":61},{"nctId":"NCT05629923","phase":"","title":"EVALUATION OF DIFFERENT PROPHYLACTIC INTERVENTIONS TOWARD COVID-19 IN SOLID ORGAN TRANSPLANT PATIENTS","status":"COMPLETED","sponsor":"University of Rome Tor Vergata","startDate":"2022-02-01","conditions":"COVID-19 Pandemic, Transplant-Related Disorder","enrollment":306},{"nctId":"NCT05234398","phase":"","title":"TIXAGEVIMAB/CILGAVIMAB Protection of Covid-19 in Transplanted Patients","status":"WITHDRAWN","sponsor":"Hospices Civils de Lyon","startDate":"2022-02","conditions":"Solid Organ Transplant Recipients","enrollment":""},{"nctId":"NCT05439044","phase":"","title":"A Real-World Study of Anti-SARS-CoV-2 Monoclonal Antibodies","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2020-03-01","conditions":"Immunocompromised Patients","enrollment":4000},{"nctId":"NCT04896541","phase":"PHASE1","title":"Phase I Double-blind, Placebo-controlled Study of AZD7442","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2021-03-16","conditions":"COVID-19","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":264,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Tixagevimab Cilgavimab","genericName":"Tixagevimab Cilgavimab","companyName":"Azienda Ospedaliera Universitaria Integrata Verona","companyId":"azienda-ospedaliera-universitaria-integrata-verona","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tixagevimab Cilgavimab is a monoclonal antibody that blocks the spike glycoprotein, classified as a blocker. It is being studied for the treatment of COVID-19, among other conditions, in clinical trials such as NCT05780437.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}